|
Didanosine (2′,3′-dideoxyinosine, ddI, DDI) marketed under the trade names Videx and Videx EC. It is an antiretroviral medication used to treat HIV/AIDS in combination with other medications as part of highly active antiretroviral therapy (HAART). It is of the reverse transcriptase inhibitor class. It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. ==Adverse effects== The most common adverse events with didanosine are diarrhea, nausea, vomiting, abdominal pain, fever, headache and rash. Peripheral neuropathy occurred in 21-26% of participants in key didanosine trials.〔 Pancreatitis is rarely observed but has caused occasional fatalities, and has black box warning status. Other reported serious adverse events are retinal changes, optic neuritis and alterations of liver functions. The risk of some of these serious adverse events is increased by drinking alcohol. In February 2010, the United States Food and Drug Administration issued a statement that patients using Didanosine (Videx) are at risk for a rare but potentially fatal liver disorder, non-cirrhotic portal hypertension.〔http://hosted.ap.org/dynamic/stories/U/US_HIV_DRUG_LIVER_RISKS?SITE=KYB66&SECTION=HOME&TEMPLATE=DEFAULT〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「didanosine」の詳細全文を読む スポンサード リンク
|